PharmTech Drug Digest 11.20
News|Articles|January 28, 2015

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-02-04-2015
  • Volume 11
  • Issue 2

Ash Stevens to Manufacture Amotosalen API

FDA has approved the Ash Steven’s manufacturing facility in Riverview, MI for the manufacture of Amotosalen.

 

Ash Stevens, a provider of global contract pharmaceutical drug substance development and API manufacturing services, announced that FDA has approved the company’s manufacturing facility in Riverview, MI for the manufacture of Amotosalen, the API in Cerus Corporation's  INTERCEPT Blood System. The INTERCEPT Blood System recently received FDA approval for ex vivo preparation of pathogenreduced plasma and platelet components in order to reduce the risk of transfusion-transmitted infection.

This represents ASI’s twelfth manufacturing approval for an innovator or new chemical entity drug.

Source: Ash Stevens

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.